New Novartis rival Kisqali hasn't slowed down Pfizer's Ibrance—at least not yet
admin 7th August 2017 Uncategorised 0Pfizer breast cancer medication Ibrance just wrapped up its first full quarter with an in-class rival, thanks to the March approval of Novartis’ Kisqali. But despite the competition, the first-to-market juggernaut has shown no signs of slowing down.
More: New Novartis rival Kisqali hasn't slowed down Pfizer's Ibrance—at least not yet
Source: fierce